Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
25.04.2024 - ~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical stage ... Seite 1
Vertex is broadening its portfolio.
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most...
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response...
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation